PDT Partners’s Inovio Pharmaceuticals INO Stock Holding History

PDT Partners’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,088	Closed	-$232K	–	832
2021 Q2	$232K	Buy	+2,088	New	+$201K	0.02%	672
2014 Q4	–	Sell	-1,292	Closed	-$153K	–	851
2014 Q3	$153K	Sell	1,292 -1,716	-57%	-$214K	﹤0.01%	1215
2014 Q2	$390K	Buy	+3,008	New	+$355K	0.01%	1107

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PDT Partners's INO Position: Q3 2021 in Review

PDT Partners sold out of Inovio Pharmaceuticals (INO) in Q3 2021, closing a stake of 2,088 shares — an estimated $232K sold.

PDT Partners first reported a position in INO in Q2 2014 and held it in 3 quarters. The position peaked at $390K in Q2 2014. 213 funds tracked by Wall St. Rank hold INO as of Q3 2021.

PDT Partners reported no remaining Inovio Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
PDT Partners sold 2,088 Inovio Pharmaceuticals shares in Q3 2021, an estimated $232K.
PDT Partners first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 3 quarters.
PDT Partners's Inovio Pharmaceuticals position peaked at $390K in Q2 2014.
213 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2021.

Based on PDT Partners's 13F filing for Q3 2021, filed 15 Nov 2021.